Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-319 first-in-human SAD/MAD placebo-controlled study in healthy adults
NL-OMON58727Phase 1Completed
- Sponsor
- Sage Therapeutics
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in disorders of gamma-aminobutyric acid signaling and cerebellar circuitry comparing SAGE-319 with Placebo (2 arms). Started Feb 2023; status: completed.
02
Drugs
SAGE-319
03
Conditions
disorders of gamma-aminobutyric acid signaling and cerebellar circuitry
Beyond the preview
Go deeper on NL-OMON58727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58727.